COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana.

Slides:



Advertisements
Similar presentations
P16INK4A expression and HPV-L1 detection in the uterine cervix: cyto-histological and immunoistochemical study M.A. Caponio, T. Addati, G. Giannone, *G.
Advertisements

56 th Annual Ob-Gyn Update New Cervical Cancer Screening Recommendations Management of Abnormal Results 56 th Annual Ob-Gyn Update New Cervical Cancer.
Clinical Use of HPV DNA Testing Thomas C. Wright, Jr. College of Physicians and Surgeons of Columbia University.
MANAGEMENT OF THE ABNORMAL PAP SMEAR
IL BCCP Questions.
Updates on Pap Smear Guidelines 2014
Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.
ASHLYN SAVAGE, MD, MSCR ASSOCIATE PROFESSOR OBSTETRICS AND GYNECOLOGY MEDICAL UNIVERSITY OF SOUTH CAROLINA Managing Abnormal Pap Smears: Incorporating.
Comparison of HPV Testing and Spectroscopy Combined with Cytology for the Detection of High- grade Cervical Neoplasia C Werner, W Griffith III, R Ashfaq,D.
Cervix Dr. Raid Jastania. Cervical Cancer Screening HPV infection Pre- Cancerous Dysplasia Cancer years.
Cervical Cancer Screening Cristin Colford, MD April 27,2010.
Screening for Cervical Cancer
Management of Women with CIN 1 or LSIL
Benign and premalignant disease of the cervix
Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening Obstetrics and Gynecology, Volume 103,
Clinical Uses of HPV DNA Testing
Case Presentations: Pre-Invasive Cervical Neoplasia
AN AUDIT OF PAP SMEAR, COLPOSCOPY AND HISTOLOGY RESULTS FROM IN TUNGARU CENTRAL HOSPITAL (KIRIBATI)
Cervical cancer prevention update
HPV: How to prevent your patients from becoming my patients Katina Robison, MD Assistant Professor, Department of Obstetrics & Gynecology Director of Colposcopy.
Cervical Cancer Screening
Screening Tests for Brest & Cervical Cancer
Review of the Guidelines for Cervical Screening in New Zealand Presentation for smear-takers September 2008.
STUDY OF MULTIMODAL HYPERSPECTROSCOPY IN A POPULATION OF WOMEN AT RISK FOR CERVICAL CANCER Olutosin Awolude α, Brenda Shultz β, Babatunde Akinwunmi α,
Cervical Cancer in California Janet Bates, MD MPH Research Program Director Research and Surveillance Program California Cancer Registry.
Screening for Cervical Cancer Max Brinsmead MB BS PhD May 2015.
Abnormal Pap in Pregnancy Alexander Burnett, MD Division Gyn Oncology, UAMS April, 2006.
SoftPAP® A Novel Collection Device for Cervical Cytology.
Current guidelines for Cervical Cancer Screening
Copyright © 2005, Duke Internal Medicine Residency Curriculum and DHTS Technology Education Services Duke Internal Medicine Residency Curriculum Screening.
In the Name of God. Screening of Cervical Cancer Pap smear and colposcopy F.Behnamfar Gynecology Oncology Fellowship Associate Professor Isfahan University.
Cervical Intraepithelial Neoplasm
KATIE OSTROM PAPS, ABORTION, AND VACUUM DELIVERY.
PRINCess Trial Prediction of Regression in CIN2. Coordinating centre in Christchurch Mainly NZ but Sydney and Melbourne just completing their approval.
TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS IN ENDOCERVIX, VAGINA, AND PERINEUM; IMPLICATIONS FOR VAGINAL SELF- COLLECTION Robert G. Pretorius, MD, Jerome L. Belinson,
Sheffield Gynaecological Cancer CentreSheffield Teaching Hospitals PRIMARY HPV SCREENING A view from colposcopy John Tidy Consultant Gynaecological Oncologist.
Cervical Cancer Screening Guidelines Update
Cytologic Findings in Type 2 Cervical Carcinomas: Some Cervical Carcinomas are more Difficult to Prevent with Screening R. Marshall Austin MD,PhD Magee-Womens.
Premalignant lesions of the cervix. Applied anatomy.
HPV testing as a Primary screening tool in England Dr Karin Denton.
Appendix 2 Comparison of screening from age 20 and age 25 Table of harms and benefits.
2006 ASCCP Consensus Guidelines Anne L. Kittendorf, MD FAAFP Assistant Professor University of Michigan Department of Family Medicine.
Kathy A. King, MD Assistant Professor of OB/GYN Medical Director, PPWI
Cervical Cancer: Experiences from a Cohort of HIV-infected Women Pascoe M, Magure T, Mudhokwani P et al Abstract: MOAB0202.
Morphologic Pap Test Findings in HPV Negative Women Age 30 Years and Older: What Information Will Be Lost with HPV Only Primary Screening? Brooke Henninger,
Cervical Cancer Screening NURS 541: Women’s Healthcare – Diagnosis and Management.
NEW SCREENING PROTOCOL WITH DUAL-STAINED CYTOLOGY TRIAGE
Trreatment of Preinvasive Lesions
Colposcopic Biopsy Results of HPV 16 and 18 patients in Bartın
Quality issues in monitoring diagnostic and treatment performance Dr
Cervical Cancer Colposcopy & Treatment
The Accuracy of Diagnostic Colposcopy Using ISCCP 2011 Classification
Efficacy of random cervical biopsy and routine endocervical curettage in subjects with normal colposcopy.
Risk factors for cervical intraepithelial neoplasia recurrence after loop electrosurgical excision procedure in HIV-1-infected and non-infected women.
Dr N Shailaja Dr Pradeep
Colposcopy triage. Satisfactory colposcopy is defined as complete visualization of the squamocolumnar epithelium, which comprises the cervical region most.
Hoa Nguyen Lam, Huyen Suong Ho Thi et al.
Updates on Pap Smear Guidelines 2014
The China Studies: A Decade of Science and Service
Figure 1: Guidelines for primary cytology# screening in South Africa
Cervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical excisional treatment of young women: A population-based study
SH-sheikhhasani Gyn-oncologist
Lessons From Implementing a Telecolposcopy Program
Differential methylation at 12 selected HPV16 CpGs in cervical cells from premalignant lesions with biopsy-confirmed diagnoses from our original study.
Fig. 3. The examinations consumed by the three cervical screening strategies to detect CIN2+/CIN3+. (A) The cases of CIN2+ detected by three current cervical.
Fig. 2. Three cervical screening strategies to detect CIN2+/CIN3+
Fig. 1. Flowchart of inclusion and exclusion criteria of the study population.ASC-US, atypical squamous cells of undetermined significance; CIN, cervical.
Cumulative probability of CIN2 stratified by HPV test results.
Presentation transcript:

COLPOSCOPY RANDOM CERVICAL BIOPSIES ENDOCERVICAL CURETTAGE S.C.P.M.G.-Fontana

I II IV III

Pretorius RG et. al. JLGTD 2011;15:180-8 PROPORTION OF CIN 3 OR CANCER (CIN 3+) DIAGNOSED BY COLPOSCOPICALLY DIRECTED BIOPSY OF A VISIBLE LESION, ‘RANDOM’ BIOPSY FROM A CERVICAL QUADRANT WITHOUT A LESION, OR SOLELY BY ECC OF CIN 3+ Colposcopically Directed ‘Random’ Solely ECC % (141/222) 25.7% (57/222) 10.8% (24/222)

1 p for trend <.001 from Pretorius RG et. al. JLGTD 2011;15:180-8 SENSITIVITY FOR CIN 3 OR CANCER (CIN 3+) OF BIOPSY OF CERVICAL QUADRANTS WITH COLPOSCOPIC IMPRESSION OF HPV, CIN, OR CANCER AS A FUNCTION OF THE NUMBER OF CERVICAL QUADRANTS WITH CIN 3+ (0 quadrants is diagnosis solely by positive ECC) 0 Quadrant with CIN 3+ 1 Quadrant with CIN 3+ 2 Quadrant with CIN 3+ 3 Quadrant with CIN 3+ 4 Quadrant with CIN 3+ Sensitivity Colposcopy 0% (0/24) 58.5% 1 (62/106) 81.1% 1 (43/53) 84.2% 1 (16/19) 100% 1 (20/20)

Yang B et. al. Gynecol Oncol 2008;110:32-6 AVERAGE EPITHELIAL THICKNESS (MICRONS) BY COLPOSCOPIC IMPRESSION AND HISTOLOGY (SELECTED REVIEW OF SPOCCS I SLIDES) HISTOLOGYCOLPO IMP NORMAL COLPO IMP LOW COLPO IMP HIGH COLPO IMP CANCER NORMAL CIN CIN CIN

Pretorius RG et. al. JLGTD 2011;15:180-8 YIELD OF CIN 3 OR CANCER PER COLPOSCOPY

COMPARISON OF CHINA COLPOSCOPY CLINIC (in which eligible women were 35 to 50 years of age, had colposcopy for cytology of Cancer, HSIL, AGUS, LSIL, or ASC-US with positive HR-HPV and were diagnosed with CIN 3+ only by cervical biopsy and/or ECC showing CIN 3+) WITH A SIMILAR MATCHED SERIES FROM S.C.P.M.G.- FONTANA China series S.C.P.M.G.-Fontana Prevalence CIN % (222/10,425) 0.2% (71/42,803) Prevalence Cancer 0.2% (21/10,425) 0.03% (13/42,803) % cervical CIN 3+ with negative colposcopy 22.7% 1 (45/198) 23.1% 1 (15/65) % CIN 3+ diagnosed by ECC of CIN % 2 (24/222) 8.5% 2 (6/71) Median age (years) % vs. 23.1%, p=.95, % vs. 8.5%, p=.57, Pretorius RG et. al. JLGTD2012;16:333-8

Pretorius RG et. al. JLGTD 2012;16:333-8 PROPORTION OF CIN 3 OR CANCER (CIN 3+) IN S.C.P.M.G.-FONTANA COLPOSCOPY CLINIC DIAGNOSED SOLELY BY ECC of CIN 2+ AGE (Years) CIN 3+ SOLELY BY ECC % (0/32) % (7/105) % (7/93) % (7/31) ≥ % (5/18) Total 9.3% (26/279)

‘RANDOM’ BIOPSIES IN CERVICAL QUADRANTS WITHOUT VISIBLE LESIONS AND ECC SHOULD BE DONE AT COLPOSCOPY FOR EVALUATION OF ABNORMAL CERVICAL CANCER SCREENING TESTS THE ECC MAY BE OMITTED ON WOMEN UNDER AGE 25 YEARS Pretorius RG et. al. JLGTD 2012;16:333-8

THANK YOU FOR YOUR ATTENTION